Agonistic autoantibodies to α1- and β2-adrenergic receptors in Alzheimer's disease and vascular dementia

摘要

1. A peptide consisting of: (i) the amino acid sequence of SEQ ID NO 1: LGYWAFGRVFCN or SEQID NO 2: PAPEDETICQINEE); (ii) the amino acid sequence identical to the amino acid sequence (i) by 70%, preferably 80% or more, preferably 90% or 95%; (iii) the amino acid sequence (i) or (ii) modified by branching or lengthening with the same or another peptide the amino acid sequence (i) or (ii) to form a homo-oligomeric or hetero-oligomeric peptide, by bringing either end of the peptide (i) - (iii) has an additional group selected from the amine, amide, acetyl, biotin, child-biotin groups, marker, spacer, linker, GKK, SGKK, or no additional group. 2. The peptide according to claim 1 for use in medical diagnostics or as a medicine. The peptide according to claim 1 or 2, characterized in that it binds to the antibodies of patients with dementia, preferably to agonistic autoantibodies that bind α and / or β adrenergic receptors. An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule consisting of a nucleotide sequence that encodes at least one peptide selected from the group consisting of the peptides of claim 1; b) a nucleic acid molecule, complementary to the nucleotide sequence a); c) a nucleic acid molecule that undergoes hybridization with the nucleotide sequence a) or b) under stringent conditions; d) a nucleic acid molecule consisting of a nucleotide sequence identical to the nucleotide sequence of a